TICKERNOMICS Sign up
Last Update: 2024-12-27 15:21:23
ABBOTT LABORATORIES ( ABT ) https://www.abbott.com
115.83USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ABT
6.40%
SPY
32.66%
-12.69%
ABT
SPY
108.59%
ABT
48.61%
SPY
302.52%
ABT
249.95%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
202479.58
206758.96
2.96
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
35.11
4.91
5.09
3.09
1.91
24.20
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
17.48
55.83
20.54
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.9696
9.40
11.45
0.72
Other Earnings and Cash Flow Stats:
ABBOTT LABORATORIES ( ABT ) Net Income TTM ($MM) is 5767.00
ABBOTT LABORATORIES ( ABT ) Operating Income TTM ($MM) is 6778.00
ABBOTT LABORATORIES ( ABT ) Owners' Earnings Annual ($MM) is 0.00
ABBOTT LABORATORIES ( ABT ) Current Price to Owners' Earnings ratio is 0.00
ABBOTT LABORATORIES ( ABT ) EBITDA TTM ($MM) is 9282.00
ABBOTT LABORATORIES ( ABT ) EBITDA Margin is 20.54%
Capital Allocation:
ABBOTT LABORATORIES ( ABT ) has paid 2.20 dividends per share and bought back 0.28899999999999 million shares in the past 12 months
ABBOTT LABORATORIES ( ABT ) has reduced its debt by 2703.0 million USD in the last 12 months
Capital Structure:
ABBOTT LABORATORIES ( ABT ) Interest-bearing Debt ($MM) as of last quarter is 12825
ABBOTT LABORATORIES ( ABT ) Annual Working Capital Investments ($MM) are -138
ABBOTT LABORATORIES ( ABT ) Book Value ($MM) as of last quarter is 39560
ABBOTT LABORATORIES ( ABT ) Debt/Capital as of last quarter is 32%
Other Balance Sheet Stats:
ABBOTT LABORATORIES ( ABT ) has 7558 million in cash on hand as of last quarter
ABBOTT LABORATORIES ( ABT ) has 14902 million of liabilities due within 12 months, and long term debt 14979 as of last quarter
ABBOTT LABORATORIES ( ABT ) has 1748 common shares outstanding as of last quarter
ABBOTT LABORATORIES ( ABT ) has 0 million USD of preferred stock value
Academic Scores:
ABBOTT LABORATORIES ( ABT ) Altman Z-Score is 5.35 as of last quarter
ABBOTT LABORATORIES ( ABT ) Piotroski Score is 8.00 as of last quarter
Corporate Governance:
ABBOTT LABORATORIES ( ABT ) largest shareholder is Heritage Wealth Advisors owning 9857 shares at 1.14 ($MM) value
ALLEN HUBERT L(an insider) Sold 150271 shares of ABBOTT LABORATORIES ( ABT ) for the amount of $17578701.58 on 2024-10-21
0.53% of ABBOTT LABORATORIES ( ABT ) is held by insiders, and 79.56% is held by institutions
ABBOTT LABORATORIES ( ABT ) went public on 1978-01-13
Other ABBOTT LABORATORIES ( ABT ) financial metrics:
FCF:5654.00
Unlevered Free Cash Flow:0.00
EPS:3.77
Operating Margin:17.48
Gross Profit Margin:55.83
Div. Payout Ratio%:66.68
Div. Growth YoY%:10.00
Equity Return%:16.54
Beta:0.72
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ABBOTT LABORATORIES ( ABT ) :
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.